PureTech Health plc (PRTC)

28.50 +0.62 (+2.24%) At close: 04:00PM EDT

PureTech Health plc

6 Tide Street
Suite 400
Boston, MA 02210
United States
617 482 2333
https://www.puretechhealth.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 96

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Bharatt M. Chowrira J.D., Ph.D.	CEO & Executive Director	800.55k	N/A	1965
Ms. Daphne Zohar	Founder, Senior Advisor & Board Observer	1.01M	N/A	1971
Dr. Robert S. Langer Jr., Ph.D.	Co-Founder & Non-Executive Director	145k	N/A	1949
Dr. Eric Elenko Ph.D.	President	N/A	N/A	1973
Dr. David R. Elmaleh Ph.D.	Co-Founder & Senior Advisor	N/A	N/A	1948
Ms. Allison Mead Talbot	Head of Communications & Investor Relations	N/A	N/A	N/A
Mr. Charles Sherwood III, J.D., Ph.D.	General Counsel & Company Secretary	N/A	N/A	N/A
Mr. Spencer Ball	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Aleksandra Filipovic M.D., Ph.D.	Head of Oncology	N/A	N/A	N/A
Ms. Cheryl Murphy Ph.D.	Head of Grants Management & Strategy	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate governance

PureTech Health plc’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 10; Board: 3; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.